Efficacy of Low-frequency rTMS in Aphasia

NCT ID: NCT05450341

Last Updated: 2022-08-30

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

20 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-07-18

Study Completion Date

2023-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In a randomized controlled trial, efficacy of low-frequency, inhibitory rTMS will be examined in rehabilitation of acquired aphasia. Two cortical sites will be targeted: Right-hemispheric homologues of Broca's and Wernicke's areas.

In addition to cognitive screening prior to onset of rTMS, language assessments will be conducted before, during and after the intervention. An eyetracking-while-listening experiment will also be conducted before and after the intervention to investigate morphosyntactic processing.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Efficacy of low-frequency (1hz), inhibitory rTMS will be examined in rehabilitation of acquired aphasia. Two cortical sites will be targeted: Right-hemispheric homologues of Broca's and Wernicke's areas. In other words, right frontal and right temporal sites will be targeted.

In addition to cognitive screening prior to onset of rTMS, language assessments will be conducted before, during and after the intervention. The language assessment will be conducted using the Turkish Aphasia Language Assessment Test (ADD) and sets of pictures used to assess naming performance. ADD will be carried out before and after the intervention. Six picture sets will be used, one at baseline, four on different days during the intervention, and the last one immediately after the last day of the intervention. Cognitive screening will be conducted at baseline using the digit span test and Raven's colored progressive matrices. In addition, a pre- and post-treatment eyetracking-while-listening experiment will be conducted to investigate morphosyntactic processing in Turkish and to examine whether the two brain stimulation interventions differentially affect online (dynamic, time-dependent) measures of morphosyntactic processing. The eyetracking paradigm will request the participants to listen to Turkish sentences varying in morphosyntactic complexity (canonical versus noncanonical sentences) and to look at the picture (out of two pictures presented on the screen) corresponding to the sentence they are listening to.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Aphasia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

The two groups receive one of the two treatments: right frontal versus right temporal stimulation.
Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Outcome Assessors
The participant and the outcomes assessor (speech and language therapist conducting the assessment tests and the eyetracking experiment) will be blind as to which experiment group the participant belongs to. The investigator / clinician providing rTMS will not be blind to the experimental condition.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Right frontal 1 Hz rTMS

Low-frequency (1 Hz) inhibitory rTMS will be administered to right inferior frontal gyrus with the following parameters:

Frequency: 1 Hz Stimulation site: Right IFG (as determined using EEG 10-20 system) Intensity: 100% of motor threshold Dosage: 20 minutes per day Duration: 10 days over 2 weeks (no stimulation during weekends)

Group Type EXPERIMENTAL

rTMS over right frontal target

Intervention Type DEVICE

Low frequency (1 Hz) rTMS over right inferior frontal gyrus

Right temporal 1 Hz rTMS

Low-frequency (1 Hz) inhibitory rTMS will be administered to right posterior superior temporal gyrus with the following parameters:

Frequency: 1 Hz Stimulation site: Right posterior superior temporal gyrus (as determined using EEG 10-20 system) Intensity: 100% of motor threshold Dosage: 20 minutes per day Duration: 10 days over 2 weeks (no stimulation during weekends)

Group Type ACTIVE_COMPARATOR

rTMS over right temporal target

Intervention Type DEVICE

Low frequency (1 Hz) rTMS over right posterior superior temporal gyrus

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

rTMS over right frontal target

Low frequency (1 Hz) rTMS over right inferior frontal gyrus

Intervention Type DEVICE

rTMS over right temporal target

Low frequency (1 Hz) rTMS over right posterior superior temporal gyrus

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Right-handedness,
* Normal or corrected-to-normal vision and hearing,
* Aphasia following cerebrovascular accident,
* Cerebrovascular accident at least 6 months prior to enrolment in the study,
* Satisfying current TMS safety guidelines (Rossi et al. 2009, 2021), which are:
* No previous history of epilepsy,
* No implant (e.g., cochlear implant) or stimulator (e.g., deep brain stimulation) in the head which may interact with the magnetic field,
* No use of central nervous system active drugs that lower seizure threshold (as listed in the aforementioned guidelines)

Exclusion Criteria

* Left-handedness, ambidexterity,
* Impaired and uncorrected vision or hearing,
* No aphasia symptoms following cerebrovascular accident,
* Time since cerebrovascular accident less than 6 months,
* Violating current TMS safety guidelines (Rossi et al. 2009, 2021). In other words:
* Having a previous history of epilepsy,
* Having an implant (e.g., cochlear implant) or stimulator (e.g., deep brain stimulation) in the head which may interact with the magnetic field,
* Taking central nervous system active drugs that lower seizure threshold (as listed in the aforementioned guidelines)
Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Medipol University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Talat Bulut

Assist. Prof. Dr.

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Talat Bulut, Ph.D.

Role: PRINCIPAL_INVESTIGATOR

Medipol University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

İstanbul Medipol University, Speech, Language and Swallowing Therapy and Research Center (MEDKOM)

Istanbul, , Turkey (Türkiye)

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Turkey (Türkiye)

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Talat Bulut, Ph.D.

Role: CONTACT

+905313327754

MEDKOM

Role: CONTACT

+90 444 85 44 ext. 1890

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Talat Bulut, PhD

Role: primary

444 85 44 ext. 1890

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Study Protocol and Statistical Analysis Plan

View Document

Document Type: Informed Consent Form

View Document

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

1

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

rTMS as a Treatment for PPA
NCT03406429 COMPLETED EARLY_PHASE1